Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Chemomab Therapeutics

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics to Present at October 2024 Investor Conferences
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics to Present at September 2024 Investor Conferences
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics Announces $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.